|
FATE | Fate Therapeutics Inc |
|
|
FATE | Fate Therapeutics Inc |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 1.16 |
| Leverage | 35.04% |
| Market Cap | $ 178.6m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -136.2m |
| Margin | -753.27% |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.